0000950103-21-016172.txt : 20211020
0000950103-21-016172.hdr.sgml : 20211020
20211020171424
ACCESSION NUMBER: 0000950103-21-016172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211018
FILED AS OF DATE: 20211020
DATE AS OF CHANGE: 20211020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34949
FILM NUMBER: 211334874
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arbutus Biopharma Corp
CENTRAL INDEX KEY: 0001447028
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980597776
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100-8900 GLENLYON PARKWAY
CITY: BURNABY
STATE: A1
ZIP: V5J 5J8
BUSINESS PHONE: 604-419-3200
MAIL ADDRESS:
STREET 1: 100-8900 GLENLYON PARKWAY
CITY: BURNABY
STATE: A1
ZIP: V5J 5J8
FORMER COMPANY:
FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp
DATE OF NAME CHANGE: 20110607
FORMER COMPANY:
FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20081003
4
1
dp160070_4-rsltd.xml
FORM 4
X0306
4
2021-10-18
0
0001447028
Arbutus Biopharma Corp
ABUS
0001635088
Roivant Sciences Ltd.
SUITE 1, 3RD FLOOR
11-12 ST. JAMES'S SQUARE
LONDON
X0
SW1Y 4LB
UNITED KINGDOM
0
0
1
0
Common shares, without par value
2021-10-18
4
C
0
22833922
A
38847462
D
Series A participating convertible preferred shares
7.13
2021-10-18
4
C
0
1164000
D
Common shares
1164000
0
D
On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms.
Includes 16,013,540 Common Shares that were previously acquired by the Reporting Person in 2015.
/s/ Matt Maisak, Authorized Signatory
2021-10-20